These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 6114889)

  • 1. Evidence for transformation of glucagon-like immunoreactivity of gut into pancreatic glucagon in vivo.
    Korányi L; Péterfy F; Szabó J; Török A; Guóth M; Tamás G
    Diabetes; 1981 Sep; 30(9):792-4. PubMed ID: 6114889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of glicentin-related peptides on glucagon secretion in anaesthetized dogs.
    Ohneda A; Kobayashi T; Nihei J
    Diabetologia; 1986 Jun; 29(6):397-401. PubMed ID: 3527839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the responses of circulating glucagon-like immunoreactivity to intraduodenal and intravenous administration of glucose.
    Unger RH; Ohneda A; Valverde I; Eisentraut AM; Exton J
    J Clin Invest; 1968 Jan; 47(1):48-65. PubMed ID: 5638120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of intestinal proglucagon-derived peptide secretion by intestinal regulatory peptides.
    Brubaker PL
    Endocrinology; 1991 Jun; 128(6):3175-82. PubMed ID: 1674688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of phenformin upon the plasma pancreatic and gut glucagon-like immunoreactivity in diabetics.
    Czyzyk A; Heding LG; Malczewski B; Miedzinska E
    Diabetologia; 1975 Apr; 11(2):129-33. PubMed ID: 168107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma glucagon-like immunoreactivity (GLI) in dogs.
    Oneda A; Horigome K; Yanbe A; Ishii S; Itabashi H
    Tohoku J Exp Med; 1975 Apr; 115(4):337-43. PubMed ID: 1145615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling.
    Scrocchi LA; Marshall BA; Cook SM; Brubaker PL; Drucker DJ
    Diabetes; 1998 Apr; 47(4):632-9. PubMed ID: 9568697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proglucagon processing in porcine and human pancreas.
    Holst JJ; Bersani M; Johnsen AH; Kofod H; Hartmann B; Orskov C
    J Biol Chem; 1994 Jul; 269(29):18827-33. PubMed ID: 8034635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Failure of somatostatin to decrease blood glucose by suppression of extrapancreatic glucagon in severely diabetic depancreatized dogs.
    Matsuyama T; Tanaka R; Shima K; Tarui S
    Endocrinol Jpn; 1978 Dec; 25(6):529-32. PubMed ID: 751798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon- and PP-related peptides of intestinal L cells and pancreatic/gastric A or PP cells. Possible interrelationships of peptides and cells during evolution, fetal development and tumor growth.
    Solcia E; Fiocca R; Capella C; Usellini L; Sessa F; Rindi G; Schwartz TW; Yanaihara N
    Peptides; 1985; 6 Suppl 3():223-9. PubMed ID: 3841689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of pancreatic glucagon gene expression in mice bearing a subcutaneous glucagon-producing GLUTag transplantable tumor.
    Drucker DJ; Lee YC; Asa SL; Brubaker PL
    Mol Endocrinol; 1992 Dec; 6(12):2175-84. PubMed ID: 1491697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioactive GLP-1 in gut, receptor expression in pancreas, and insulin response to GLP-1 in diabetes-prone rats.
    Valverde I; Wang GS; Burghardt K; Kauri LM; Redondo A; Acitores A; Villanueva-Peñacarrillo ML; Courtois P; Sener A; Cancelas J; Malaisse WJ; Scott FW
    Endocrine; 2004 Feb; 23(1):77-84. PubMed ID: 15034199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decrease in blood glucose and release of gut glucagon-like immunoreactive materials by bombesin infusion in the dog.
    Matsuyama T; Namba M; Nonaka K; Tarui S; Tanaka R; Shima K
    Endocrinol Jpn; 1980 Dec; 27 Suppl 1():115-9. PubMed ID: 7014201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic somatostatin is a mediator of glucagon inhibition by hyperglycemia.
    Klaff LJ; Taborsky GJ
    Diabetes; 1987 May; 36(5):592-6. PubMed ID: 2883057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A-Cell and gut glucagon in normal and depancreatized dogs. Inhibition by somatostatin and insulin.
    Matsuyama T; Wider MD; Tanaka R; Shima K; Tarui S; Nishikawa M; Foà PP
    Diabete Metab; 1979 Jun; 5(2):141-7. PubMed ID: 478084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of acetylcholine on the secretion of gut glucagon immunoreactivity and gut glucagon-like immunoreactivity in pancreatectomized dogs.
    Yoshida T; Kondo M
    Endocrinol Jpn; 1980 Feb; 27(1):33-8. PubMed ID: 6993193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of total pancreatectomy on the secretion of gut glucagon in humans.
    Yasui K
    Jpn J Surg; 1983 Mar; 13(2):122-9. PubMed ID: 6350663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential processing of regulatory peptide precursors in pancreas and gut: studies of proglucagon and prosomatostatin processing.
    Baldissera FG
    Dan Med Bull; 1994 Feb; 41(1):79-92. PubMed ID: 7910545
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of bombesin on plasma insulin, pancreatic glucagon, and gut glucagon in man.
    Bruzzone R; Tamburrano G; Lala A; Mauceri M; Annibale B; Severi C; de Magistris L; Leonetti F; Delle Fave G
    J Clin Endocrinol Metab; 1983 Apr; 56(4):643-7. PubMed ID: 6339534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue-specific differences in the levels of proglucagon-derived peptides in streptozotocin-induced diabetes.
    Brubaker PL; So DC; Drucker DJ
    Endocrinology; 1989 Jun; 124(6):3003-9. PubMed ID: 2721455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.